The Adaptor Complex 2 Directly Interacts with the {alpha}1b-Adrenergic Receptor and Plays a Role in Receptor Endocytosis*

Dario Diviani, Anne-Laure Lattion, Liliane Abuin, Olivier Staub and Susanna Cotecchia {ddagger}

From the Institut de Pharmacologie et de Toxicologie, Faculté de Médecine, 1005 Lausanne, Switzerland

Received for publication, February 28, 2003
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Using the yeast two-hybrid system, we identified the µ2 subunit of the clathrin adaptor complex 2 as a protein interacting with the C-tail of the {alpha}1b-adrenergic receptor (AR). Direct association between the {alpha}1b-AR and µ2 was demonstrated using a solid phase overlay assay. The {alpha}1b-AR/µ2 interaction occurred inside the cells, as shown by the finding that the transfected {alpha}1b-AR and the endogenous µ2 could be coimmunoprecipitated from HEK-293 cell extracts. Mutational analysis of the {alpha}1b-AR revealed that the binding site for µ2 does not involve canonical YXX{Phi} or dileucine motifs but a stretch of eight arginines on the receptor C-tail. The binding domain of µ2 for the receptor C-tail involves both its N terminus and the subdomain B of its C-terminal portion. The {alpha}1b-AR specifically interacted with µ2, but not with the µ1, µ3, or µ4 subunits belonging to other AP complexes. The deletion of the µ2 binding site in the C-tail markedly decreased agonist-induced receptor internalization as demonstrated by confocal microscopy as well as by the results of a surface receptor biotinylation assay. The direct association of the adaptor complex 2 with a G protein-coupled receptor has not been reported so far and might represent a common mechanism underlying clathrin-mediated receptor endocytosis.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Desensitization to the effects of hormones and neurotransmitters is a fundamental regulatory mechanism of G protein-coupled receptor (GPCR)1 function defined by a specific loss of responsiveness for those receptors that have been repeatedly stimulated by the agonist. Receptor desensitization results from the combination of multiple biochemical events occurring at different time frames: receptor-G protein uncoupling in response to receptor phosphorylation (seconds to minutes), internalization or endocytosis of cell surface receptors to intracellular compartments (minutes), and down-regulation of the total pool of receptors due to their decreased synthesis and/or increased degradation (hours) (1). A prominent role in homologous desensitization of GPCRs is played by G protein-coupled receptor kinases. Once the receptor is occupied by the agonist, it is recognized by the G protein-coupled receptor kinases and becomes phosphorylated (2). The subsequent uncoupling of the receptor from the G protein is then mediated by arrestin proteins, which preferentially bind to the agonist-occupied phosphorylated receptor (3). However, during the last decade, {beta}-arrestins have emerged as key regulatory molecules controlling various steps of receptor desensitization. Beyond their role in physical uncoupling of GPCRs from the G proteins (3), it has been demonstrated that {beta}-arrestins target GPCRs to the endocytic machinery (4). In fact, it is believed that for those GPCRs that internalize in a clathrin-dependent manner, like the {beta}2-adrenergic receptor (AR), targeting of the receptor-{beta}-arrestin complexes to clathrin-coated vesicles is mediated by a dual interaction of {beta}-arrestin with both clathrin heavy chain and the {beta}2 subunit of the heterotetrameric clathrin adaptor complex 2 (AP2) (5, 6, 7).

The AP2 complex directly links the clathrin coat with cargo transmembrane proteins that are sorted into coated pits and vesicles (8) and is composed of two large subunits, {alpha} and {beta}2, of about 100 kDa and two smaller subunits, µ2 and {sigma}2, of 50 and 17 kDa, respectively (9). The AP2 adaptor can initiate endocytosis of membrane receptors by either associating directly with their cytoplasmic tail or by interacting with additional molecules, such as {beta}-arrestins, as described for the {beta}2-AR (5, 7). Direct interactions between AP2 and transmembrane proteins have been demonstrated, for example, for the transferrin receptor (10), the epidermal growth factor receptor (11, 12), and the cystic fibrosis transmembrane conductance regulator (13) but not for GPCRs. They are principally mediated by the µ2 subunit, which specifically associates with endocytosis signals including YXX{Phi} (where {Phi} represents a bulky hydrophobic residue) (14) and dileucine motifs (15) on the cytoplasmic portion of the transmembrane proteins (8). Interestingly, recent evidence suggests that the {beta}2 subunit also participates in the recognition of dileucine motifs on the proteins (16).

Previous reports have shown that the {alpha}1b-AR undergoes rapid endocytosis upon exposure to the agonist. This was shown both in DDT1-FM2 smooth muscle cells expressing endogenous receptors as well as in cells expressing the recombinant receptor (17, 18). The molecular determinants involved in agonist-induced endocytosis of the {alpha}1b-AR reside within the C-tail of the receptor as demonstrated by the fact that truncation of this region almost completely abolished receptor desensitization and internalization (19). A previous report suggested that the {alpha}1b-AR can internalize in clathrin-coated vesicles as shown by that fact that {alpha}1b-AR endocytosis can be blocked by hypertonic sucrose and that internalized receptors colocalize with transferrin receptors (18). Moreover, we previously reported that agonist-induced internalization of the {alpha}1b-AR is, at least in part, mediated by {beta}-arrestins (20). Despite this experimental evidence, our knowledge on the biochemical mechanisms and the molecular mediators controlling the clathrin-mediated endocytosis of the {alpha}1b-AR is still at an early stage.

To identify new proteins interacting with the {alpha}1b-AR that could potentially be involved in regulating receptor function, we have used the yeast two-hybrid system and identified the µ2 subunit of the AP2 complex. In this study, we demonstrate that the {alpha}1b-AR and µ2 subunit can directly interact through a polyarginine motif located on the C-tail of the receptor and that this interaction plays a role in agonist-induced internalization of the receptor. Our findings highlight a previously unappreciated mechanism that might also be involved in the endocytosis of other GPCRs.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Expression Constructs—A cDNA fragment encoding the last 165 amino acids of the hamster {alpha}1b-AR (amino acids 351–515) (Fig. 2) was PCR-amplified and subcloned at EcoRI/SalI in pGEX4T1, pET30a, and pLexA plasmids to construct fusion proteins with GST, His6, and LexA at the N terminus of the C-tail of the receptor, respectively. For constructing GST fusion proteins with different fragments of the C-tail, cDNA fragments encoding amino acids 351–380, 351–395, 351–425, 351–449, and 351–477 of the {alpha}1b-AR were PCR-amplified and subcloned at EcoRI/SalI in pGEX4T1. The Y386A, Y447A, L450A/L451A, and L473A/L474A mutations were introduced into the C-tail-pGEX4T1 and C-tail-pLexA plasmids by standard PCR-directed mutagenesis using the Pwo DNA polymerase (Roche Applied Science).



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 2.
Topological model of the {alpha}1b-AR. The YXX{Phi} and dileucine motifs are highlighted by solid lines. The bars indicate the position of the stop codons introduced to construct the truncated C-tail fragments of the {alpha}1b-AR (T368, T380, T395, T425, T449, and T477), named after the number of the last encoded amino acid. The box includes the eight arginines deleted in the {triangleup}371–378 receptor mutant. The amino acids mutated to disrupt the YXX{Phi} and dileucine motifs are also indicated.

 

The full-length cDNA encoding the human µ2 subunit was PCR-amplified from EST 3538047 (accession number BE264960 [GenBank] ) and subcloned at HindIII-SalI in pEGFPN3 and pGEX4T1 to generate fusion proteins with GFP at the C terminus and GST at the N terminus of µ2, respectively. The full-length cDNAs encoding human µ1, µ3, and µ4 subunits identified in other AP complexes were PCR-amplified from EST 4954703 (accession number BG920410 [GenBank] ), EST 720361 (accession number AA2611409), and EST 748897 (accession number AI644755 [GenBank] ), respectively, and subcloned at EcoRI/SalI in pEGFPN3 to construct fusion proteins with GFP at the C terminus. For generating fusion proteins with GFP at the C terminus, DNA fragments encoding amino acids 1–163, 164–282, and 283–435 of µ2 were PCR-amplified and subcloned at HindIII/SalI into pEGFPN3.

The full-length cDNA encoding the hamster {alpha}1b-AR (21) was PCR-amplified and inserted into the pEGFPN1 using EcoRI/AgeI to fuse GFP at the C terminus of the receptor ({alpha}1b-GFP). The T368-GFP and {triangleup}371–378-GFP receptor mutants were constructed by PCR-directed mutagenesis of the {alpha}1b-GFP using the Pwo DNA polymerase (Roche Applied Science). To construct HA-tagged receptor forms, the N-terminal fragment of the wild type {alpha}1b-AR was amplified using primers encoding the HA (YPYDVPDYA) epitope at the 5' end and subcloned into the pRK5 vector encoding the wild type receptor or its mutants.

Yeast Two-hybrid Screening—The yeast strain L40 was transformed with the C-tail-pLexA plasmid encoding the {alpha}1b-AR C-tail fused to LexA, and clones were selected and subsequently transformed with 250 µg of a human brain Matchmaker cDNA library in the pACT2 vector (Clontech). Of 13 million double transformants, 40 exhibited moderate to strong growth on histidine-deficient plates. The library plasmids isolated from positive clones were used to cotransform the L40 strain with either the C tail-pLexA or the empty pLexA plasmid, and the specificity of the interactions was confirmed by growth on histidine-deficient plates as well as by {beta}-galactosidase activity (Yeast Protocols Handbook; Clontech).

Expression and Purification of Recombinant Proteins in Bacteria— GST-tagged fusion proteins of µ2 and {alpha}1b-AR C-tail were expressed using the bacterial expression vector pGEX4T1 in the BL21DE3 strain of Escherichia coli and purified. Bacterial extracts containing GST fusion proteins were prepared by centrifugation of bacterial cultures, followed by lysis of the pelleted bacteria in buffer A (20 mM Tris, pH 7.4, 50 mM NaCl, 5 mM MgCl2, 0.5% (w/v) Triton X-100, 1 mM benzamidine, 2 µg/ml leupeptin, 2 µg/ml pepstatin), sonication, and centrifugation at 38,000 x g for 30 min at 4 °C. After incubating the supernatants with glutathione-Sepharose beads (Amersham Biosciences) for 2 h at 4 °C, the resin was washed with 10 bed volumes of buffer A and stored at 4 °C. GST fusion proteins were eluted from the resin with 5 mM reduced glutathione for 15 min at room temperature, dialyzed, and stored at -20 °C.

His6-tagged fusion protein of the {alpha}1b-AR C-tail was expressed using the bacterial expression vector pET30 in BL21DE3 bacteria and purified. Extracts containing His6-tagged fusion proteins were prepared by centrifugation of bacterial cultures and lysis of pelleted bacteria in buffer B (20 mM Hepes, pH 7.8, 500 mM NaCl, 10 mM imidazole, 1 mM benzamidine, 2 µg/ml leupeptin, 2 µg/ml pepstatin). After a 1-min sonication, the lysates were centrifuged at 38,000 x g for 30 min at 4 °C. The His6-tagged fusion proteins were purified by incubating the supernatant with nickel-nitrilotriacetic acid chelating resin (Amersham Biosciences) for 1 h at 4 °C. The resin was then washed five times with 10 bed volumes of buffer B and stored at 4 °C. His6-tagged fusion proteins were eluted from the resin with 20 mM Hepes, pH 7.8, 500 mM NaCl, 300 mM imidazole, 1 mM benzamidine, 2 µg/ml leupeptin, 2 µg/ml pepstatin for 1 h at room temperature, dialyzed, and stored at -20 °C. The protein content of the eluates was assessed by Coomassie staining of SDS-PAGE gels.

Cell Culture and Transfections—HEK-293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and gentamycin (100 µg/ml) and transfected at 50–80% confluence in 35- or 100-mm dishes using the calcium-phosphate method. After transfection, cells were grown for 48 h in DMEM supplemented with 10% fetal calf serum before harvesting. The total amount of transfected DNA was of about 0.5–1 µg/35-mm dish and 10 µg/100-mm dish.

GST Pull-down and Immunoprecipitation Experiments—For GST pull-down, HEK-293 cells expressing the various constructs grown in 100-mm dishes were lysed in 1 ml of buffer C (20 mM Tris, pH 7.4, 100 mM NaCl, 5 mM EDTA, 1% (w/v) Triton X-100, 5 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) and centrifugation at 100,000 x g for 30 min at 4 °C. Glutathione-Sepharose beads coupled to the different GST fusion proteins were incubated with 1.5 mg of proteins derived from the cell lysates in a total volume of 1 ml overnight at 4 °C. The beads were then washed five times with buffer C and resuspended in SDS-PAGE sample buffer. Eluted proteins were analyzed by SDS-PAGE and Western blotting.

For immunoprecipitation experiments, HEK-293 cells expressing the various HA-tagged constructs grown in 100-mm dishes were lysed in 1 ml of buffer D (20 mM Tris, pH 7.4, 100 mM NaCl, 5 mM EDTA, 1% digitonin, 5 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride). Cell lysates were incubated overnight at 4 °C on a rotating wheel. The solubilized material was centrifuged at 100,000 x g for 30 min at 4 °C, and the supernatant was incubated for 4 h at 4 °C with 5 µg of a rabbit anti-HA polyclonal antibody (Santa Cruz) or with control nonimmune IgG. After the addition of 40 µl of protein A-Sepharose, the incubation was continued for 2 h at 4 °C, followed by a brief centrifugation on a bench top centrifuge. The pellet was washed five times with buffer D and twice with PBS and then dissolved in SDS-PAGE sample buffer for 1 h at 37 °C. Imunoprecipitated proteins were analyzed by SDS-PAGE and Western blotting.

SDS-PAGE and Western Blotting—Samples were denatured in SDS-PAGE sample buffer (65 mM Tris, 2% SDS, 5% glycerol, 5% {beta}-mercaptoethanol, pH 6.8) for 1 h at room temperature, separated on 10% acrylamide gels and electroblotted onto nitrocellulose membranes. The blots were incubated in TBS-Tween (100 mM Tris, pH 7.4, 140 mM NaCl, 0.05% Tween 20) containing 5% (w/v) nonfat dry milk overnight at room temperature, washed three times with TBS-Tween, and then incubated with the specific primary antibody diluted in TBS-Tween for 2 h at room temperature. After three washes with TBS-Tween, the membranes were probed with horseradish peroxidase-conjugated secondary anti-mouse antibodies (Amersham Biosciences) for 1 h, washed three times with TBS-Tween, and developed using the enhanced chemiluminescence detection system (Amersham Biosciences).

The following affinity-purified primary antibodies were used for immunoblotting: mouse monoclonal anti-HA (200 µg/ml, 1:250 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), mouse monoclonal anti-GFP (400 µg/ml, 1:500 dilution; Roche Applied Science), mouse monoclonal anti-µ2 (1:250 dilution; Transduction Laboratories), mouse monoclonal anti-{alpha}-adaptin (1:250 dilution; Transduction Laboratories), and mouse monoclonal anti-{beta}-adaptin (1:250 dilution; Transduction Laboratories).

Solid Phase Overlay Assay—After SDS-PAGE and electroblotting of the samples, the nitrocellulose filters were incubated with TBS-Tween containing 5% (w/v) nonfat dry milk and 1% bovine serum albumin for 1 h at room temperature and with 100,000 cpm/µl of32P-labeled His6-tagged {alpha}1b-AR C-tail in TBS-Tween containing 5% nonfat dry milk and 0.1% bovine serum albumin for 16 h at room temperature. After extensive washes in TBS-Tween, the blots were visualized by autoradiography.

Purified His6-tagged C-tail (4 µg) was radiolabeled following its incubation with the catalytic subunit of protein kinase A (0.1 µg) and [{gamma}-32P]ATP (50 µCi) in 50 mM MOPS, pH 6.8, 50 mM NaCl, 2 mM MgCl2, 1 mM dithiothreitol, 0.1 mg/ml bovine serum albumin for 1 h at 30 °C. The radiolabeled protein was separated from free [{gamma}-32P]ATP on an Excellulose GF-5 desalting column (Pierce) equilibrated in TBS-Tween.

Confocal Microscopy—HEK-293 cells grown on glass coverslips were transfected with the cDNAs encoding different GFP-tagged receptors. 48 h after transfection, cells were incubated in serum-free DMEM for 1 h and treated for various times with 10-4 M epinephrine (Sigma) at 37 °C. After the treatment, cells were placed on ice, washed twice with ice-cold PBS, fixed for 10 min in PBS plus 3.7% formaldehyde, and mounted using Prolong (Molecular Probes, Inc., Eugene, OR). In the experiments measuring the effect of K44A dynamin mutant on receptor endocytosis, HEK-293 cells were cotransfected with the cDNAs encoding the GFP-tagged {alpha}1b-AR and the HA-tagged dynamin K44A mutant. 48 h after transfection, cells were incubated in serum-free DMEM for 1 h and treated for 1 h with 10-4 M epinephrine at 37 °C. After two washes with ice-cold PBS, cells were fixed for 10 min in PBS plus 3.7% formaldehyde and permeabilized for 5 min with 0.2% (w/v) Triton X-100 in PBS. Cells were incubated in PBS plus 1% bovine serum albumin for 1 h and with 1:250 dilution of anti-HA polyclonal antibody (Santa Cruz Biotechnology) for 1 h, followed by another incubation with Texas Red-conjugated donkey anti-rabbit secondary antibody (Jackson ImmunoResearch) for 1 h. The cells were then mounted using Prolong (Molecular Probes). GFP fluorescence or immunofluorescent staining were visualized on a laser-scanning confocal microscope (Zeiss).

Cell Surface Biotinylation Experiments—HEK-293 cells grown in 100-mm dishes were transfected with the cDNAs encoding the HA-tagged {alpha}1b-AR or its T368 and {triangleup}371–378 mutants. 48 h after transfection, cells were incubated in serum-free DMEM for 1 h and treated for various times with 10-4 M epinephrine (Sigma) at 37 °C. After the incubation, cells were placed on ice and washed twice with ice-cold PBS. Surface proteins were biotinylated by incubating cells with 500 µg/ml of the membrane-impermeable biotin analogue sulfo-NHS-S-S-biotin (Pierce) in PBS for 30 min at 4 °C. Unreacted biotin was quenched and removed by three washes with ice-cold TBS at 4 °C. Biotinylated cells were then lysed with hypo-osmotic buffer (10 mM Tris, pH 7.4, 5 mM EDTA, 5 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride), and the cellular homogenate was centrifuged at 30,000 x g for 15 min at 4 °C. The pellet was resuspended in buffer D (20 mM Tris, 100 mM NaCl, 5 mM EDTA, 1% digitonin, 5 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride), sonicated for 30 s, and stirred for 6 h at 4 °C. The solubilized material was centrifuged at 100,000 x g for 30 min at 4 °C, and the supernatant was incubated overnight with 40 µl of streptavidin-Sepharose beads (Amersham Biosciences) at 4 °C. The beads were pelleted by brief centrifugation and washed five times with buffer D and twice with PBS. Biotinylated proteins were eluted by incubating the beads with 200 mM dithiothreitol for 2 h at 37 °C and separated on SDS-PAGE followed by Western blotting. The biotinylated receptors were revealed by immunoblotting using anti-HA monoclonal antibodies (Santa Cruz Biotechnology) as described above. The intensity of the band was quantified by densitometry of films exposed in the linear range, imaged using the Molecular Imager FX (Bio-Rad), and analyzed using NIH Image software (National Institutes of Health). In control experiments, we determined that the biotinylation reagent did not cross the plasma membrane, as shown by the fact that the catalytic subunit of protein kinase A, which is cytoplasmic, could not be detected in streptavidin-Sepharose precipitates (results not shown).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Identification of the µ2 Subunit of the AP2 Complex as a Protein Interacting with the {alpha}1b-AR—It was previously reported that the C-tail of the {alpha}1b-AR plays an important role in the regulation of receptor desensitization and internalization (19, 22, 23). However, the molecular players involved in these processes are not fully characterized. To identify novel regulatory proteins interacting with the C-tail of the {alpha}1b-AR, the last 165 amino acids of the receptor were used as bait to screen a human brain cDNA library using the yeast two-hybrid system. Three independent positive clones encoding the µ2 subunit of the AP2 complex were identified from 13 x 106 cotransformants, as assessed by their ability to grow in the absence of histidine and to produce {beta}-galactosidase. To confirm the interaction between the C-tail of the receptor and µ2, the L40 yeast strain was transformed with the bait plasmid expressing the C-tail of the {alpha}1b-AR ({alpha}1b-AR C-tail-pLexA) in combination with either a pACT2 vector containing the µ2 cDNA (µ2-pACT2) or with empty pACT2 vector. As shown in Fig. 1A, yeast transformed with µ2-pACT2 were able to grow in the absence of histidine (upper panel) and to produce {beta}-galactosidase (lower panel), whereas those transformed with the empty pACT2 vector did not.



View larger version (33K):
[in this window]
[in a new window]
 
FIG. 1.
Identification of the µ2 subunit of the AP2 complex as a protein interacting with the C-tail of the {alpha}1b-AR. A, yeast two-hybrid screening. The C-tail-pLexA plasmid was used to transform the L40 yeast strain in combination with either empty pACT2 vector or with a pACT2 containing the µ2 cDNA. Double transformants were plated on Trp-, Leu-, His- plates to select for histidine prototrophy (upper panel). The His+ positive clones encoding µ2 were restreaked on selective medium and assayed for {beta}-galactosidase activity by a filter assay (lower panel). Quantitative analysis of the interaction between the C-tail and µ2 was performed using the liquid {beta}-galactosidase assay. B, GST pull-down assay. Extracts from HEK-293 cells expressing endogenous µ2 were incubated with glutathione-Sepharose beads coupled to GST alone or to the GST-C-tail. The µ2 eluted from the beads was detected by Western blotting using anti-µ2 monoclonal antibodies (left panel). The amount of extract loaded on the gel was 10% of that used for the pull-down. A control protein staining indicating the expression level of the GST and GST-tagged C-tail used in the pull-down assay is shown (right panel). The results are representative of three independent experiments. C, solid phase overlay assay. GST or GST-µ2 proteins were separated on SDS-PAGE and electroblotted onto nitrocellulose membranes. The membrane was incubated with 100 nM of32P-labeled His6-tagged C-tail (left panel) and revealed by autoradiograpghy. A protein staining showing the relative amount of GST and GST-µ2 used in the assay is shown (right panel). The results are representative of three independent experiments. IB, immunoblot.

 

To provide biochemical evidence that the {alpha}1b-AR can associate with the µ2 subunit of the AP2 complex, pull-down experiments were performed by incubating the GST-tagged C-tail of the receptor with cell extracts of HEK-293 cells. We found that the µ2 endogenously expressed in HEK-293 cells specifically bound to GST-C-tail but not to GST alone (Fig. 1B).

To assess whether the association between the {alpha}1b-AR and the µ2 subunit of the AP2 complex occurs through a direct interaction or is mediated through another protein, we monitored the ability of purified GST-µ2 to associate with the purified His6-tagged C-tail using a solid phase overlay assay. The autoradiography shown in Fig. 1C (left panel) indicates that the C-tail of the32P-labeled His6-tagged C-tail of the {alpha}1b-AR could specifically interact with GST-µ2, but not with GST alone. Control experiments showed that the GST-µ2 did not interact with 100 nM of an unrelated radiolabeled protein (regulatory subunit of protein kinase A) (results not shown). Altogether, these results strongly suggest that the µ2 subunit of the AP2 complex can directly interact with the C-tail of the {alpha}1b-AR.

Identification of the Binding Site for µ2 on the {alpha}1b-AR—The µ2 subunit of the AP2 complex has been shown to recognize endocytosis signals including tyrosine-based motifs (YXX{Phi}) and dileucine motifs on the cytoplasmic portion of membrane receptors (9). Analysis of the primary sequence of the C-tail of the {alpha}1b-AR revealed the presence of two potential tyrosine-based motifs at positions 386 and 442 and of two potential dileucine motifs at positions 450 and 473 (Fig. 2). Moreover, two additional YXX{Phi} sequences can be found at positions 144 and 153 in the second intracellular loop of the receptor (Fig. 2). To assess whether these motifs can mediate the interaction between the {alpha}1b-AR and µ2, we generated GST-C-tail fusion proteins in which tyrosines 386 and 442 as well as the leucine doublets 450–451 and 473–474 were individually substituted by alanines and assessed their ability to interact with µ2 endogenously expressed in HEK-293 cells. Surprisingly, none of these mutations was able to disrupt the interaction between the C-tail of the receptor and µ2 (Fig. 3A). Similar results were obtained using the yeast two-hybrid system as an interaction assay (Fig. 3B). To investigate whether the two YXX{Phi} sequences located at positions 144 and 153 of the {alpha}1b-AR were involved in the interaction with µ2, we also constructed a GST fusion protein, including the second intracellular loop of the receptor. This fusion protein was not able to interact with the µ2 from HEK-293 cell extracts (results not shown). Altogether, these results suggest that the structural determinants of the {alpha}1b-AR mediating its interaction with µ2 are different from the canonical tyrosine-based or dileucine motifs.



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 3.
Mapping the binding site for µ2 on the {alpha}1b-AR. A, extracts from HEK-293 cells expressing endogenous µ2 were incubated with glutathione-Sepharose beads coupled to GST alone or to GST-tagged C-tail fragments carrying point mutations of the YXX{Phi} and dileucine motifs. The µ2 eluted from the beads was detected by Western blotting using anti-µ2 monoclonal antibodies. The amount of extract loaded on the gel was 10% of that used for the pull-down. A control protein staining indicated that the expression level of each GST-tagged C-tail fragment was similar in the different samples (results not shown). The results are representative of three independent experiments. B, empty pLexA vector or pLexA encoding different C-tail constructs was used to transform the L40 yeast strain in combination with the pACT2 vector containing the µ2 cDNA. Quantitative analysis of the interaction between the various C-tail constructs and µ2 was performed using the liquid {beta}-galactosidase assays. C, extracts from HEK-293 cells expressing endogenous µ2 were incubated with glutathione-Sepharose beads coupled to GST alone or to GST-tagged C-tail fragments carrying different truncations as indicated in Fig. 2. The µ2 eluted from the beads was detected as indicated in A. The amount of extract loaded on the gel was 10% of that used for the pull-down. A control protein staining indicated that the expression level of each GST-tagged C-tail fragment was similar in the different samples (results not shown). Results are representative of three independent experiments. IB, immunoblot.

 

To further investigate the binding site for µ2 on the C-tail of the {alpha}1b-AR, we fused to GST a series of fragments of the C-tail carrying progressive truncations (Fig. 2) and assessed their ability to interact with µ2 endogenously expressed in HEK-293 cells. As shown in Fig. 3C, whereas different fusion constructs truncated up to residue 380 could interact with µ2, the GST-T368 fusion construct did not, thus suggesting that the region included between residues 380 and 368 is crucial for this interaction. Interestingly, the deletion of eight arginines at positions 371–378 completely abolished the binding of the C-tail to µ2, suggesting that the {alpha}1b-AR interacts with the µ2 subunit of the AP2 complex through a novel arginine-based binding domain (Fig. 2).

Identification of the Binding Site for the {alpha}1b-AR on µ2 Recently, the crystal structure of the µ2 subunit of the AP2 complex has been solved (12, 24). The first 157 residues of the protein are organized in a predominantly {alpha}-helical structure, whereas the C-terminal fragment of µ2 is largely composed of {beta}-sheet structures that are folded into two subdomains (Fig. 4A) (12). The first subdomain, comprising residues 158–282, contains the binding site for tyrosine-based endocytic motifs, whereas the second subdomain, comprising residues 283–435, contains an interaction site for synaptotagmin, a neuronal AP2-binding protein involved in synaptic vesicles exocytosis (25).



View larger version (31K):
[in this window]
[in a new window]
 
FIG. 4.
Identification of the binding site for the {alpha}1b-AR on µ2. A, schematic representation of the µ2 fragments fused to GFP. Fragment 1–157 corresponds to the N-terminal domain, whereas fragments 158–282 and 283–435 correspond to the subdomain A and subdomain B of the C-terminal portion, respectively. B, GST alone and GST-C tail were coupled to glutathione-Sepharose beads and incubated with extracts from HEK-293 cells overexpressing the different GFP-tagged µ2 fragments. The µ2 fragments eluted from the beads were detected by Western blotting using anti-GFP monoclonal antibodies. The amount of extract loaded on the gel was 10% of that used for the pull-down. Results are representative of three independent experiments. IB, immunoblot.

 

To identify the region within µ2 that interacts with the C-tail of the {alpha}1b-AR, we tagged with GFP the three fragments of the µ2, 1–157, 158–282, and 283–435, and expressed them in HEK-293 cells. Pull-down experiments were performed by incubating the GST-C-tail construct with cell extracts overexpressing different GFP-tagged µ2 fragments (Fig. 4A). We found that the 1–157 and 282–435 fragments retained the ability to bind the C-tail of the {alpha}1b-AR, whereas the 158–257 fragment did not (Fig. 4B). These findings led us to conclude that the molecular determinants of µ2 involved in the recognition of the polyarginine motif on the C-tail of the {alpha}1b-AR are located on two domains at the N and C terminus, respectively, of the µ2 molecule. Interestingly, these domains are distinct from the µ2 region that binds tyrosine-based internalization signals, which is located between residues 157 and 282 (12).

The {alpha}1b-AR2 Interaction Occurs in the Cells and Is Regulated by Agonist-induced Receptor Activation—To demonstrate that the {alpha}1b-AR and µ2 can form a complex inside the cells, we performed coimmunoprecipitation experiments from HEK-293 cells transiently expressing the HA-tagged {alpha}1b-AR. After immunoprecipitating the receptor using polyclonal anti-HA antibodies, monoclonal anti-HA as well as anti-µ2 antibodies were used to immunoblot the immunoprecipitated samples. The Western blots revealed that the µ2 endogenously expressed in HEK-293 cells could specifically co-immunoprecipitate with the {alpha}1b-AR, whereas no bands were immunoprecipitated by IgG (Fig. 5A, top panel, lanes 2 and 3). These findings demonstrate that beyond their ability to interact in vitro, the {alpha}1b-AR and µ2 can associate inside the cells.



View larger version (48K):
[in this window]
[in a new window]
 
FIG. 5.
Association of the {alpha}1b-AR with the AP2 complex in the cells. A, HEK-293 cells were transfected with the cDNAs encoding the HA-tagged forms of the {alpha}1b-AR (lanes 1–3) or of its mutants T368 (lanes 3–6) and {triangleup}371–378 (lanes 7–9). Receptor expression was 1–2 pmol/mg of protein for all receptors. Cell lysates were subjected to immunoprecipitation with the nonimmune IgG or anti-HA polyclonal antibodies. Western blots of the immunoprecipitates and of the cell extracts (Ex.) were revealed using anti-µ2 monoclonal antibodies (upper panel) to detect the endogenous µ2 or anti-HA monoclonal antibodies to detect the recombinant receptors (lower panel). The amount of extract loaded on the gel was 10% of that used for the immunoprecipitation. B, HEK-293 cells were transfected with the cDNAs encoding the HA-tagged forms of the {alpha}1b-AR (lanes 1–3) or of its mutant {triangleup}371–378 (lanes 3–6). Western blots of the immunoprecipitates and of the cell extracts (Ex.) were revealed using anti-{alpha} adaptin (upper panel), anti-{beta}2 adaptin (middle panel), or anti-HA (lower panel) monoclonal antibodies to detect the endogenous {alpha} and {beta}2 subunits of the AP2 complex and the recombinant receptors, respectively. One of the two bands recognized by the anti-{alpha} adaptin antibody in the cell extract that is not coimmunoprecipitated might be nonspecific. The results are representative of three independent experiments. IB, immunoblot.

 

To confirm that the {alpha}1b-AR/µ2 interaction in intact cells was mediated by the polyarginine motif identified above as the binding site for µ2, coimmunoprecipitation experiments were performed from HEK-293 cells overexpressing the HA-tagged receptor mutants truncated at residue 368 (T368) or carrying a deletion of the polyarginine motif ({triangleup}371–378). The T368 and {triangleup}371–378 receptor mutants displayed pharmacological properties similar those of the wild type {alpha}1b-AR (results not shown). In addition, as previously shown (26), tagging the wild type or mutated receptors with HA or GFP at their N and C terminus, respectively, did not affect the pharmacological properties of the receptor (results not shown). As shown in Fig. 5A, the endogenous µ2 did not coimmunoprecipitate either with the T368 or with the {triangleup}371–378 receptor mutants, thus suggesting that the polyarginine stretch between residues 371 and 378 represents the only binding site of the {alpha}1b-AR for µ2.

To investigate whether the whole heterotetrameric AP2 complex could interact with the {alpha}1b-AR, we determined whether additional subunits of the AP2 complex could be coimmunoprecipitated with the receptor. As shown in Fig. 5B, the {alpha} and {beta}2 subunits endogenously expressed in HEK-293 cells were coimmunoprecipitated with the wild type receptor but not with the {triangleup}371–378 receptor mutant, thus suggesting that the whole AP2 complex can associate with the {alpha}1b-AR through the interaction mediated by its µ2 subunit.

To assess whether the {alpha}1b-AR/µ2 interaction could be modulated by the agonist-induced activation of the receptor, HEK-293 cells expressing the HA-tagged {alpha}1b-AR were incubated for 15 min in the absence or presence of 10-4 M epinephrine prior to immunoprecipitation of the receptor. As shown in Fig. 6, treatment with epinephrine induced a 2-fold increase in the amount of endogenous µ2 coimmunoprecipitated with receptor when compared with untreated cells (Fig. 6, A (lanes 6 and 8) and B). This strongly suggests that the {alpha}1b-AR/µ2 interaction is dynamically regulated by the agonist-induced activation of the {alpha}1b-AR, which might increase the amount of µ2 associated with the receptor.



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 6.
Effect of agonist-induced receptor activation on the {alpha}1b-AR/µ2 interaction. A, nontransfected HEK-293 cells (NT) (lanes 1, 3, 5, and 7) and cells transfected with the cDNA encoding the HA-tagged {alpha}1b-AR (IB; lanes 2, 4, 6, and 8) were incubated for 15 min in the absence (Basal) or presence (EPI) of 10-4 M epinephrine. Cell lysates were subjected to immunoprecipitation with anti-HA polyclonal antibodies. Western blots of cell extracts (lanes 1–4) and immunoprecipitates (lanes 4–8) were revealed using anti-µ2 (upper panel) and anti-HA (lower panel) monoclonal antibodies to detect endogenous µ2 and the recombinant receptor, respectively. The amount of extract loaded on the gel was 10% of that used for the immunoprecipitation. Results are representative of four independent experiments. B, densitometry of the bands corresponding to µ2 coimmunoprecipitated with the HA-tagged {alpha}1b-AR in the absence (Basal) or presence (EPI) of 10-4 M epinephrine. The amount of µ2 in the immunoprecipitates was normalized to the µ2 content of the cell extracts. Results are the mean ± S.E. of four independent experiments. *, p < 0.05 (Student's t test) compared with basal.

 

Specificity of the {alpha}1b-AR2 Interaction—So far, four different adaptor protein complexes (APs) involved in sorting of membrane proteins have been identified and characterized (9). AP1 is involved in the formation of clathrin-coated vesicles from the trans-Golgi network and the trafficking of proteins from the trans-Golgi network to the plasma membrane (8). AP2 plays a role in the clathrin-mediated endocytosis of plasma membrane receptors (8). AP3 has been shown to mediate the sorting of proteins form early endosomes to lysosomes (27). Finally, AP4 has been shown to participate in the polarized transport of proteins to the basolateral membrane in Madin-Darby canine kidney cells (28). To assess whether the {alpha}1b-AR preferentially associates with the AP2 as compared with other AP complexes, we performed coimmunoprecipitation experiments from HEK-293 expressing the HA-tagged {alpha}1b-AR and GFP-tagged µ1, µ2, µ3, and µ4 subunits. Interestingly, Western blotting using anti-GFP antibodies indicated that, whereas µ2 could be coimmunoprecipitated with the HA-tagged {alpha}1b-AR, µ1, µ3, and µ4 could not (results not shown). This suggests that, inside the cells, the {alpha}1b-AR specifically associates with the µ2 subunit of the AP2 complex rather than with other AP complexes.

The {alpha}1b-AR2 Interaction Is Involved in Clathrin-mediated Endocytosis of the Receptor—To confirm that the {alpha}1b-AR can internalize in clathrin-coated vesicles, we assessed whether hypertonic sucrose and the overexpression of a dominant negative mutant of dynamin (K44A) could inhibit the agonist-induced internalization of the GFP-tagged {alpha}1b-AR transiently expressed in HEK-293 cells. Incubation of cells with 0.45 M sucrose for 15 min prior to stimulation with epinephrine completely inhibited agonist-induced internalization (Fig. 7, C and D). Similarly, overexpression of the K44A dynamin mutant impaired receptor endocytosis when compared with control cells (Fig. 7, E and F). These results support the notion that in HEK-293 cells the {alpha}1b-AR undergoes internalization through clathrin-mediated endocytosis.



View larger version (54K):
[in this window]
[in a new window]
 
FIG. 7.
The {alpha}1b-AR internalizes through clathrin-mediated endocytosis. Confocal microscopy of HEK-293 cells transfected with the cDNA encoding the GFP-tagged {alpha}1b-AR alone (A–D) or in combination with that coding for the HA-tagged dynamin mutant K44A (E and F) is shown. Cells were treated for 60 min in the absence (Untreated) or presence (EPI) of 10-4 M epinephrine. The cells expressing the GFP-tagged {alpha}1b-AR were incubated for 15 min in the absence (A and B) or presence (C and D) of 0.45 M sucrose prior to epinephrine stimulation. Cells were then fixed, permeabilized, and stained using anti-HA monoclonal antibodies to detect the dynamin mutant as indicated under "Experimental Procedures." GFP-tagged {alpha}1b-AR was directly visualized by excitation at 488 nm. The images are representative of five independent experiments.

 

It is well established that the AP2 complex controls the early steps of membrane receptor endocytosis, allowing clathrin to be recruited to the receptor. Since the {alpha}1b-AR represents the first GPCR to be shown to directly interact with AP2, and since this interaction seems to occur through a noncanonical µ2 binding motif on the receptor, we sought to establish whether the {alpha}1b-AR/µ2 interaction might play a role in the regulation of receptor endocytosis.

To test this hypothesis, we determined whether deleting the µ2 binding site on the C-tail of the {alpha}1b-AR could affect agonist-induced receptor internalization. The GFP-tagged forms of the wild type {alpha}1b-AR (WT-GFP) and of its mutants T368 (T368-GFP) and {triangleup}371–378 ({triangleup}371–378-GFP) were transiently expressed in HEK-293 cells and tested for their ability to undergo agonist-induced internalization. Cells expressing the different GFP-tagged receptors were treated with 10-4 M epinephrine for 15, 30, and 60 min, and agonist-induced internalization was assessed by monitoring receptor redistribution by confocal microscopy. As shown in Fig. 8 (upper panels), incubation of cells expressing the WT-GFP receptor with epinephrine caused a rapid redistribution of the receptor from the cell surface to intracellular compartments. Internalization was already detectable 15 min after agonist exposure, whereas a more pronounced redistribution was observed after 60 min. The T368-GFP receptor was completely impaired in its ability to undergo internalization (Fig. 8, middle panels) in agreement with our previous findings indicating that the integrity of the C-tail is required for receptor endocytosis and desensitization (19). Interestingly, epinephrine-induced endocytosis of the {triangleup}371–378-GFP receptor mutant was delayed as compared with that of the WT-GFP receptor (Fig. 8, lower panels). In fact, internalization was barely detectable after 30 min of exposure to the agonist, and at 60 min a significant portion of the receptor was still present at the cell surface. Altogether, these results strongly suggest that the {alpha}1b-AR/µ2 interaction is involved in receptor internalization, since receptor mutants lacking the binding site for µ2 are clearly impaired in receptor endocytosis.



View larger version (35K):
[in this window]
[in a new window]
 
FIG. 8.
Internalization of the {alpha}1b-AR and of its mutants monitored by confocal microscopy. Confocal microscopy of HEK-293 cells transfected with the cDNAs encoding the GFP-tagged forms of the {alpha}1b-AR (WT-GFP) and of its mutants T368 (T368-GFP) and {triangleup}371–378 ({triangleup}371–378-GFP). After treatment with 10-4 M epinephrine for the indicated times, cells were fixed, and GFP-tagged receptor was directly visualized by excitation at 488 nm. The images are representative of five independent experiments.

 

To quantify receptor endocytosis, we used a biotinylation assay to selectively label the receptors expressed at the cell surface. HEK-293 cells expressing HA-tagged forms of the wild type {alpha}1b-AR (HA-WT) and of its mutants T368 (HA-T368) and {triangleup}371–378 (HA-{triangleup}371–378) were exposed to 10-4 M epinephrine for various times and subsequently incubated with a membrane-impermeant biotinylation reagent (sulfo-NHS-biotin) (see "Experimental Procedures"). Biotinylated cell surface receptors were precipitated using streptavidin-Sepharose beads and detected by Western blotting using anti-HA antibodies. The results of this biochemical assay indicated that the HA-WT, HA-T368, and HA-{triangleup}371–378 receptors were expressed at similar levels at the cell surface (Fig. 9, lanes 1, 5, and 9). HA-tagged receptors could not be detected in streptavidin-Sepharose precipitates when cells were not incubated with the biotinylation reagent, thus confirming that, in our experimental conditions, only biotinylated receptors could be isolated (results not shown).



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 9.
Internalization of the {alpha}1b-AR and of its mutants monitored by biotinylation of the receptors at the cell surface. A, HEK-293 cells were transfected with the cDNAs encoding the HA-tagged forms of the {alpha}1b-AR (lanes 1–4) and of its mutants T368 (lanes 5–8) and {triangleup}371–378 (lanes 9–12). After treatment with 10-4 M epinephrine for the indicated times, cells were incubated with 500 µM NHS-S-S-biotin for 30 min at 4 °C. Surface biotinylated receptors were precipitated using streptavidin-Sepharose beads, separated on SDS-PAGE, electroblotted onto nitrocellulose membranes, and detected by Western blotting using anti-HA monoclonal antibodies. Western blot analysis performed on cell lysates using anti-HA monoclonal antibodies indicated that the receptor expression levels were similar in the different samples (results not shown). Results are representative of three independent experiments. B, densitometry of the bands corresponding to the biotinylated receptors precipitated by the streptavidin-Sepharose beads was performed as indicated under "Experimental Procedures." Results are the mean ± S.E. of three independent experiments.

 

Treatment of cells expressing the HA-WT receptor with 10-4M epinephrine induced a rapid receptor endocytosis, which was 23% after 15 min, 61% after 30 min, and 80% after 60 min (Fig. 9, lanes 1–4). As expected, the HA-T368 receptor mutant was resistant to agonist-induced internalization as demonstrated by the fact that 94% of the receptors were still present at the cell surface after 60 min of exposure to epinephrine (Fig. 9, lanes 5–8). In agreement with the results of confocal imaging (Fig. 8), epinephrine-induced internalization of the HA-{triangleup}371–378 receptor mutant was significantly decreased compared with that of the wild type receptor with 60% of the receptor remaining at the cell surface after a 60-min exposure to the agonist (Fig. 9, lanes 9–12). Altogether, these findings support the hypothesis that agonist-induced internalization of the {alpha}1b-AR is controlled, at least in part, by the interaction of µ2 with the C-tail of the receptor.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
This study provides the evidence that the AP2 complex can associate with a G protein-coupled receptor, the {alpha}1b-AR, through the direct interaction of its µ2 subunit with the receptor. This represents, to our knowledge, the first report of a direct interaction between the AP2 complex and a GPCR. Previous studies have shown that the AP2 complex is implicated in the agonist-induced endocytosis of the {beta}2-AR (5, 6, 7). However, in this case, the AP2 complex seemed to be recruited to the receptor through {beta}-arrestins which can directly interact with the {beta}2 subunit of AP2.

One unexpected finding of our study was the observation that µ2 recognizes a noncanonical binding motif on the {alpha}1b-AR, which consists of eight consecutive arginines included between residues 371 and 378 of the C-tail of the receptor (Fig. 3). Deletion of this motif completely abolished the {alpha}1b-AR/µ2 interaction inside the cells measured in the coimmunoprecipitation experiments (Fig. 5). Interestingly, the deletion of the µ2 binding motif also abolished the interaction of the {alpha}1b-AR with the {alpha} and {beta} subunits of the AP2 complex, suggesting that this motif represents the only point of contact between the AP2 complex and the receptor. The polyarginine motif of the {alpha}1b-AR is reminiscent of the binding site for µ2 previously identified in synaptotagmin, a neuronal AP2 binding proteins involved in recycling of synaptic vesicles, which contains six positively charged residues (KRLKKKK) (29).

The recent publication of the crystal structure of the entire AP2 complex has provided a better understanding of how the different subunits of the complex contact each other and of how the µ2 subunit interacts with tyrosine-based endocytic motifs located on membrane receptor (24). Whereas the YXXF motifs have been shown to bind to a hydrophobic pocket located in the subdomain A (residues 157–282) of µ2, recent studies indicate that the positively charged motif of synaptotagmin contacts the subdomain B (residues 283–435) of µ2 (25). Similarly, we could show that the subdomain B (residues 283–435) together with the N-terminal region of µ2 (residues 1–157) participate in the interaction with the polyarginine motif of the {alpha}1b-AR (Fig. 4). Therefore, it appears that the N-terminal region and the subdomain B of µ2 might provide a docking surface for positively charged motifs exposed on the cytoplasmic face of membrane receptors. A systematic scanning mutagenesis of these domains will be required to determine whether the {alpha}1b-AR and synaptotagmin bind to similar structural determinants of the µ2.

The {alpha}1b-AR/µ2 interaction is dynamically regulated as demonstrated by the fact that activation of the receptor by the agonist increases the association of µ2 to the receptor by 2-fold (Fig. 6). This suggests that µ2 preferentially recognizes the agonist-occupied form of the {alpha}1b-AR. One can speculate that binding of epinephrine to the {alpha}1b-AR might trigger a conformational change that exposes the polyarginine motif, thus promoting the association of the receptor with the AP2 complex. A similar model has been proposed for the epidermal growth factor receptor-mediated recruitment of the AP2 complex in which the receptor exposes a high affinity binding site for µ2 only upon activation by epidermal growth factor (11, 12).

An important finding of our study is that the interaction of the {alpha}1b-AR with µ2 of the AP2 complex plays a role in receptor endocytosis. This was mainly demonstrated by the fact that deleting the µ2 binding motif in the C-tail of the {alpha}1b-AR markedly decreased agonist-induced receptor internalization as shown by confocal microscopy (Fig. 8) as well as by surface receptor biotinylation (Fig. 9). Hypertonic sucrose as well as the dominant negative dynamin mutant K44A almost completely inhibited epinephrine-induced endocytosis of the GFP-tagged {alpha}1b-AR, thus supporting the notion that the {alpha}1b-AR can internalize in clathrin-coated vesicles (Fig. 7). Since the AP2 complex links the clathrin coat to transmembrane proteins sorted into coated pits, the {alpha}1b-AR/µ2 interaction might represent a mechanism directly involved in targeting the {alpha}1b-AR to clathrin-coated vesicles.

In a previous study, we reported that agonist-induced internalization of the {alpha}1b-AR is, at least in part, mediated by {beta}-arrestins. This was mainly demonstrated by two observations: (a) the stimulation of the {alpha}1b-AR with epinephrine induced a marked translocation to the cell surface of {beta}-arrestin; (b) a dominant negative mutant of {beta}-arrestin 1 (V53D) decreased the internalization of the {alpha}1b-AR (20). Therefore, in addition to the direct association of the receptor with the AP2 complex, {beta}-arrestins also play an important role in the clathrin-mediated endocytosis of the {alpha}1b-AR. This is supported by the observation that the deletion of the µ2 binding motif did not completely abolish receptor internalization, suggesting that additional mechanisms regulate the endocytosis of the {alpha}1b-AR (Figs. 8 and 9). Interestingly, overexpression of a dominant negative mutant of {beta}-arrestin 1 (V53D) (30) abolished the residual internalization observed for the {triangleup}371–378 mutant of the {alpha}1b-AR lacking the µ2-binding site (results not shown). Additional determinants involved in receptor endocytosis are likely to be localized on the C-tail of the {alpha}1b-AR, since the T368 receptor mutant, lacking most of the C-tail, was almost totally impaired in its ability to undergo agonist-induced internalization (Figs. 8 and 9). Altogether, these findings suggest that agonist-induced endocytosis of the {alpha}1b-AR results from multiple mechanisms involving the interaction of the receptor with both the AP2 complex and {beta}-arrestins.

The findings of our study suggest that the molecular mechanisms underlying the internalization of the {alpha}1b-AR seem to differ from those controlling the endocytosis of other GPCRs, like the {beta}2-AR, for which it is believed that their redistribution to clathrin-coated vesicles is mediated by {beta}-arrestins. However, the possibility that GPCRs can directly interact with the AP2 complex has not been investigated so far, and it will be important to establish whether this interaction represents a common mechanism occurring at other GPCRs in addition to the {alpha}1b-AR. The discovery that the AP2 complex can directly interact with the {alpha}1b-AR raises several questions about the molecular mechanisms underlying receptor endocytosis. In particular, future studies will aim at elucidating the relationship between the structural determinants of the {alpha}1b-AR involved in binding the AP2 complex versus {beta}-arrestins, the respective role of the AP2 complex and {beta}-arrestins in targeting the receptor to clathrin-coated vesicles as well as their interplay with other yet unidentified mechanisms regulating receptor trafficking and function.


    FOOTNOTES
 
* This work was supported by Fonds National Suisse de la Recherche Scientifique Grant 31-5104.97. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Institut de Pharmacologie et de Toxicologie, Rue du Bugnon 27, 1005 Lausanne, Switzerland. Tel.: 41-21-692-5400; Fax: 41-21-692-5355; E-mail: Susanna.Cotecchia{at}ipharm.unil.ch.

1 The abbreviations used are: GPCR, G protein-coupled receptor; AR, {alpha}1b-adrenergic receptor; AP1, -2, -3, and -4, adaptor complex 1, 2, 3, and 4, respectively; EST, expressed sequence tag; GFP, green fluorescent protein; GST, glutathione S-transferase; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; HA, hemagglutinin; NHS, N-hydroxysuccinimide. Back


    ACKNOWLEDGMENTS
 
We acknowledge Monique Nenniger-Tosato for excellent technical assistance and Dr. Laura Stanasila for constructing the cDNA encoding the GFP- and HA-tagged {alpha}1b-AR constructs and for critical reading of the manuscript.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ferguson, S. S. (2001) Pharmacol. Rev. 53, 1–24[Abstract/Free Full Text]
  2. Kohout, T. A., and Lefkowitz, R. J. (2003) Mol. Pharmacol. 63, 9–18[Free Full Text]
  3. Perry, S. J., and Lefkowitz, R. J. (2002) Trends Cell Biol. 12, 130–138[CrossRef][Medline] [Order article via Infotrieve]
  4. Goodman, O. B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447–450[CrossRef][Medline] [Order article via Infotrieve]
  5. Laporte, S. A., Oakley, R. H., Zhang, J., Holt, J. A., Ferguson, S. S., Caron, M. G., and Barak, L. S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3712–3717[Abstract/Free Full Text]
  6. Laporte, S. A., Miller, W. E., Kim, K. M., and Caron, M. G. (2002) J. Biol. Chem. 277, 9247–9254[Abstract/Free Full Text]
  7. Kim, Y. M., and Benovic, J. L. (2002) J. Biol. Chem. 277, 30760–30768[Abstract/Free Full Text]
  8. Pearse, B. M., Smith, C. J., and Owen, D. J. (2000) Curr. Opin. Struct. Biol. 10, 220–228[CrossRef][Medline] [Order article via Infotrieve]
  9. Robinson, M. S., and Bonifacino, J. S. (2001) Curr. Opin. Cell Biol. 13, 444–453[CrossRef][Medline] [Order article via Infotrieve]
  10. Collawn, J. F., Stangel, M., Kuhn, L. A., Esekogwu, V., Jing, S. Q., Trowbridge, I. S., and Tainer, J. A. (1990) Cell 63, 1061–1072[Medline] [Order article via Infotrieve]
  11. Sorkin, A., Mazzotti, M., Sorkina, T., Scotto, L., and Beguinot, L. (1996) J. Biol. Chem. 271, 13377–13384[Abstract/Free Full Text]
  12. Owen, D. J., and Evans, P. R. (1998) Science 282, 1327–1332[Abstract/Free Full Text]
  13. Weixel, K. M., and Bradbury, N. A. (2001) J. Biol. Chem. 276, 46251–46259[Abstract/Free Full Text]
  14. Ohno, H., Stewart, J., Fournier, M. C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., Kirchhausen, T., and Bonifacino, J. S. (1995) Science 269, 1872–1875[Medline] [Order article via Infotrieve]
  15. Rodionov, D. G., and Bakke, O. (1998) J. Biol. Chem. 273, 6005–6008[Abstract/Free Full Text]
  16. Rapoport, I., Chen, Y. C., Cupers, P., Shoelson, S. E., and Kirchhausen, T. (1998) EMBO J. 17, 2148–2155[Abstract/Free Full Text]
  17. Leeb-Lundberg, L. M. F., Cotecchia, S., DeBlasi, A., Caron, M., and Lefkowitz, R. J. (1987) J. Biol. Chem. 262, 3098–3105[Abstract/Free Full Text]
  18. Fonseca, M. I., Button, D. C., and Brown, R. D. (1995) J. Biol. Chem. 270, 8902–8909[Abstract/Free Full Text]
  19. Lattion, A. L., Diviani, D., and Cotecchia, S. (1994) J. Biol. Chem. 269, 22887–22893[Abstract/Free Full Text]
  20. Mhaouty-Kodja, S., Barak, L. S., Scheer, A., Abuin, L., Diviani, D., Caron, M. G., and Cotecchia, S. (1999) Mol. Pharmacol. 55, 339–347[Abstract/Free Full Text]
  21. Cotecchia, S., Schwinn, D. A., Randall, R. R., Lefkowitz, R. J., Caron, M. G., and Kobilka, B. K. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7159–7163[Abstract]
  22. Diviani, D., Lattion, A. L., Larbi, N., Kunapuli, P., Pronin, A., Benovic, J. L., and Cotecchia, S. (1996) J. Biol. Chem. 271, 5049–5058[Abstract/Free Full Text]
  23. Diviani, D., Lattion, A. L., and Cotecchia, S. (1997) J. Biol. Chem. 272, 28712–28719[Abstract/Free Full Text]
  24. Collins, B. M., McCoy, A. J., Kent, H. M., Evans, P. R., and Owen, D. J. (2002) Cell 109, 523–535[Medline] [Order article via Infotrieve]
  25. Haucke, V., Wenk, M. R., Chapman, E. R., Farsad, K., and De Camilli, P. (2000) EMBO J. 19, 6011–6019[Abstract/Free Full Text]
  26. Bjorklof, K., Lundstrom, K., Abuin, L., Greasley, P. J., and Cotecchia, S. (2002) Biochemistry 41, 4281–4291[CrossRef][Medline] [Order article via Infotrieve]
  27. Madrid, R., Le Maout, S., Barrault, M. B., Janvier, K., Benichou, S., and Merot, J. (2001) EMBO J. 20, 7008–7021[Abstract/Free Full Text]
  28. Simmen, T., Honing, S., Icking, A., Tikkanen, R., and Hunziker, W. (2002) Nat. Cell Biol. 4, 154–159[CrossRef][Medline] [Order article via Infotrieve]
  29. Chapman, E. R., Desai, R. C., Davis, A. F., and Tornehl, C. K. (1998) J. Biol. Chem. 273, 32966–32972[Abstract/Free Full Text]
  30. Ferguson, S. S. G., Downey, W. E., Colapietro, A. M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 271, 363–366[Abstract]